Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX-826 (Pyrilutamide) for Androgenetic Alopecia in Chinese Men
NCT06126965Phase 3Active, not recruiting
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Kintor Pharmaceutical Limited. Started Dec 2021; status: active, not recruiting.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06126965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126965.